ALNYLAM PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Realized Gain (Loss)
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-14.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2019-02-14
- ALNYLAM PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2018-12-31 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2018-09-30 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2017-12-31 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2017-09-30 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2018 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2017 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2016 was $0.00.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $0.00 derived: sum of 2 quarters · filed 2019-02-14 | $0.00 10-K · filed 2019-02-14 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 | ||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-02 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $0.00 derived: sum of 2 quarters · filed 2019-02-14 | $0.00 10-K · filed 2019-02-14 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-02 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |